



FALL 2001

Prestigious NCI Grant Supports UCSF Prostate Cancer Research

UCSF's research into prostate cancer detection, treatment and prevention has received a welcome infusion of support with a highly coveted, five-year, \$11.9 million grant award from the National Cancer Institute (NCI). The Specialized Program of Research Excellence (SPORE) grant is unusual because it includes funding for basic science and clinical research.

The SPORE grant was awarded to UCSF in recognition of the breadth and depth of the UCSF Comprehensive Cancer Center's basic science and clinical research programs and its ability to integrate these programs for clinical advances. The NCI has awarded only 27 SPORE grants, 6 of them in prostate cancer, since the funding program was established in 1992.

The NCI grant has been augmented by an additional \$12 million in matching funds raised by the UCSF prostate cancer advocacy group led by Intel chairman Andy Grove and Yahoo! board member Art Kern (see story, page 4).

"Our goal with this SPORE is to bring together outstanding scientists and clinicians from different disciplines to solve the significant problems in prostate cancer research," said Marc A. Shuman, MD, professor of medicine and urology, and principal investigator of the UCSF prostate SPORE.

"When you get clinicians and basic scientists working together, you're able to make rapid progress," said Peter Carroll, MD, professor and chair of the Department of Urology, who serves as co-principal investigator of the prostate SPORE.

The new SPORE will initially support the six research programs outlined below. The research emphasis may change as new discoveries are made. The SPORE also includes six core resource programs that provide support to the research effort: administrative, tissue, informatics, advocacy, clinical research and animal technology.

Mechanisms of Hormone Resistance in Prostate Cancer

Virtually all prostate cancers initially respond to treatment with anti-androgens, drugs that block the activity of male hormones. Eventually, however, tumors become resistant to hormonal therapy. This SPORE project, led by principal investigator Keith Yamamoto, PhD, and co-principal investigator Mika Kakefuda, MD, will study how changes in the androgen receptor found in tumor cells cause prostate cancer to progress to hormone-independent disease. Understanding these changes could lead to improved treatments. The research team includes co-investigator Marc Shuman, MD.

Researchers will explore how the androgen receptor changes as disease progresses and how these changes affect the binding of different molecules, including hormones.

Using microarray technology developed at the UCSF Cancer Center, the team will attempt to identify genes that are expressed in hormone-dependent and hormone-independent prostate cancer. This work will be performed with patient specimens obtained at the time of diagnosis and later, when disease becomes hormone-independent. One goal of this work is to determine whether there

(see SPORE on page 3)

UCSF UROLOGY

CONTENTS

SPORE grant	1
Letter from the chair	2
Advocacy	4
Hypospadias center	5
Clinical trials	5
Derr-Chevron endowed chair	6
Tanagho honored	6
Hinman research lab	7
Recent publications	8
Honors & awards	9
Recent grants awarded	9
New faculty	10
New residents	11
In memoriam	11
Faculty	12

Letter from the chair



Peter R. Carroll, MD

It has been an exciting and productive year for the Department of Urology at UCSF. We have entered into an ambitious and much-needed expansion and renovation of our academic, laboratory and patient care areas. This last fall, our Program in Urologic Oncology moved to the third floor of the new UCSF Comprehensive Cancer Center. This move has allowed physicians from a variety of disciplines to see patients in a more timely fashion due to an increase in space and staffing. Support services have been consolidated to one site. New programs in imaging, high-risk patient evaluation and psychosocial support are being implemented. Currently, approximately 1,000 patients are seen monthly at this site. I fully anticipate that this number will continue to grow as recruitments in urology and medical oncology are filled. We have just begun renovation and expansion of our academic and clinical space at the Parnassus Campus. The entire east wing of the Ambulatory Care Center will be renovated to accommodate both our academic and patient care needs. As part of this expansion, a fully equipped fluoroscopy unit will be constructed to allow for state-of-the-art endoscopic and urodynamic evaluation in an outpatient setting.

Our research programs remain a priority at UCSF. This summer will complete the building of our new laboratories in the Health Sciences Tower. The laboratory will be named in honor of Dr. Frank Hinman, Jr., one of our department's finest physicians and scientists. The Frank Hinman, Jr., Urological Research Laboratory will serve the needs of a variety of investigators. UCSF is beginning an ambitious project to build new and much-needed research space at the Mt. Zion site. The department will partner with the University in this effort, as new research space is urgently needed to support the rapid growth of our scientific programs.

We in the department as well as those from a variety of other departments and divisions here at UCSF are very proud of our designation as a Specialized Program of Research Excellence in prostate cancer (SPORE). This is a prestigious recognition awarded to very few institutions. I am very grateful to all those who worked hard to submit this grant. I am especially grateful to Dr. Marc Shuman, professor of medicine and urology, who spearheaded our efforts, and to our advocates, who raised substantial resources to supplement this grant so we could expand our objectives.

I would like to welcome our four new residents: Drs. Adam Hittelman, Sarah Janssen and Susan Logan, who join us at the PGY 1 level, and Dr. Kirsten Greene, who joins our program at the PGY 2 level. We attracted a record number of applicants last year, interviewing approximately 40 of the very best. These residents were our top choices and we know that they are the future leaders in our field. Three new faculty members, Drs. June Chan, Christopher Kane and Hiep Thieu Nguyen, represent key recruitments in the areas of epidemiology, minimally invasive surgery and pediatric urology.


It is with deep appreciation that I acknowledge the department's first endowed chair, the Ken and Donna Derr–Chevron Endowed Chair in Prostate Cancer. I am honored to be the first recipient of this chair. This honor reflects not only my deep respect for Mr. and Mrs. Derr, but also the generosity and vision of Chevron Corporation to support our battle against prostate cancer.


The future of this department is bright. We enjoy strong clinical, financial and academic health, allowing us to expand our efforts in areas where we can uniquely improve the lives of patients with urological diseases. We take very seriously our tripartite mission to educate, to care and to discover. We are driven to excel at each. I remain very grateful to my faculty, housestaff, the leadership of UCSF and our patient advocates who have allowed us to achieve and maintain our status as a program of excellence.

Sincerely,

A handwritten signature in black ink that reads "Peter R. Carroll".

Peter R. Carroll, MD
Professor and Chair of Urology
Ken and Donna Derr–Chevron Endowed Chair in Prostate Cancer






Graphical visualization of a common breast cancer amplicon on chromosome 20q13.2 and subcellular localization of a pair of genes encoded in the amplicon. The ZNF217 gene has recently been shown to promote immortalization of human epithelial cells when overexpressed. ZNF217 maps to a controversial prostate cancer susceptibility locus and is expressed in prostate tumors. The role of ZNF217 in prostate tumor progression is under investigation in Collins' laboratory.

ZNF217

Prefoldin 4



(SPORE from page 1)

are reliable genetic markers of disease progression. This work complements that of Colin Collins, PhD (see below).

After identifying several genes that seem to be critical to the development of hormone-independent prostate cancer, researchers will study how they are regulated by the androgen receptor.

Genomics of Prostate Cancer

What role do genes play in the course of prostate cancer? Researchers have already located several "candidate" genes that may play a role in the disease. This team, led by principal investigator Collins and co-principal investigator Peter Carroll, MD, will identify genes that suppress or promote cancer growth in tumor samples. The project should yield information about the genes involved in the development and progression of prostate cancer and help identify new therapeutic targets. The research team includes co-investigators Joe Gray, PhD, and June Chan, ScD.

In an effort to identify prognostic markers, researchers will perform comparative genomic hybridization (CGH), a scanning technique that identifies areas in which chromosomes may be abnormally copied, on samples from 100 prostate tumors. These samples will be taken from patients who underwent prostatectomy and appear to be at intermediate risk of disease progression.

In addition, researchers will test for the presence of markers that appear to be implicated in progression in a larger sample of 800 tumors.

The project team will sequence key genes within areas of chromosomal abnormality and thoroughly analyze those that are associated with disease progression.

Based on these results, patients at high risk of disease recurrence could be treated with experimental techniques in an attempt to reduce recurrence.

Developing a Model of Viral Therapy for Prostate Cancer

Adenovirus vectors are currently being developed as potential therapies for many types of cancer, including prostate cancer. Their usefulness in prostate cancer depends on developing systems for delivering virus effectively to tumor cells, especially those that have spread from the primary site.

This project, led by principal investigator Frank McCormick, PhD, and co-principal investigator Katherine Rauen, MD, PhD, will develop a mouse model for the use of therapeutic adenoviruses, which will make clinical testing of these agents more feasible. The project will work with mice susceptible to prostate cancer and use a mouse adenovirus that is similar in many ways to human adenoviruses. The research team includes Mack Roach III, MD.

Researchers will grow and characterize a number of mouse adenovirus mutants, then inoculate mice with these viruses in a number of ways (injection, infusion, etc.) to determine how the virus is distributed in tissues. They will then examine in vivo the ability of these mutant viruses to infect and destroy mouse prostate tumors. Researchers will also study the efficacy of adenovirus treatment when combined with radiation therapy, information that will pave the way for a future clinical trial.

The project team will examine specimens of human prostate tumors to determine the distribution of the primary human adenovirus receptor in cancers of various stages. Such information is important because the level of receptors on the cell surface will affect how well adenoviral therapy will work.

Generating Antibodies for Prostate Cancer Diagnosis and Therapy

A research team led by principal investigator James Marks, MD, PhD, and co-principal investigator Gary

(see SPORE on page 4)



(SPORE from page 3)

Grossfeld, MD, will work to identify antigens on the surface of prostate tumor cells that differ from those present on normal cells. Such antigens can be targeted by monoclonal antibodies to kill cancer cells, either directly or by delivering therapeutic drugs. They can also be used in diagnostic and prognostic tests.

Antibody-based therapies are available for non-Hodgkins lymphoma and breast cancer. Researchers are optimistic that such therapy can be developed for prostate cancer.

The project will use advanced technology to generate antibodies from “libraries” of collected human cell samples. In the past, this type of research has used rodent cells to generate antibodies, which caused some adverse immunological reactions when used in human subjects.

Identifying Prostate Tumor Susceptibility Genes in Mice

Principal investigator Allan Balmain, PhD, and co-principal investigator Marc Shuman, MD, will work to identify genes that play a role in the progression of prostate cancer in mice bred to develop the disease. This work will draw on knowledge previously gained in studying the genetics of skin tumor growth in the same mice strains.

Specific aims of the project are to identify genes that affect the survival time of mice with prostate cancer and those that affect tumor angiogenesis, number of tumors and tu-

mor grade. Tumor samples will also be analyzed to find variations in gene expression in tumors at different stages of progression. This work will complement that of Collins, who is performing similar studies in human prostate tumors.

Antibody Immunologic Therapy for Prostate Cancer

This project, led by principal investigator Eric Small, MD, and co-principal investigator James Allison, PhD, will develop and evaluate a series of new immunological therapies for patients with prostate cancer. The therapy will be based on blocking CTLA4, a molecule that inhibits T-cell response to antigens. Work in mice has shown that blocking CTLA4 with an anti-CTLA4 antibody improves antitumor immune responses, particularly when used with another immune stimulator, GM-CSF. A phase I study in human subjects suggested that this could be a promising avenue of therapy.

The project will study the effectiveness of blocking CTLA4 in mice susceptible to prostate cancer. Researchers will then evaluate its use in prostate cancer patients who have minimal residual disease after prostatectomy or radiation therapy. After more testing in animals, the researchers anticipate offering additional clinical trials combining the CTLA4-blocking strategy with other new immunological approaches.

Advocates raise \$12 million for prostate cancer research

UCSF owes its National Cancer Institute (NCI) designation as a prostate cancer research center in part to the energetic work of an advocacy group organized by several Bay Area economic leaders. The group raised \$12 million to fund prostate cancer research at the UCSF Cancer Center over the next five years. That figure matches the \$12 million granted by the NCI with its designation of the UCSF prostate cancer effort as a Specialized Program of Research Excellence (SPORE).


Led by Intel chairman Andy Grove and Yahoo! board member Arthur Kern, along with Kathleen Sullivan Alioto, Brian Bean, Denny Crow, Arthur Rock, Stan Rosenfeld, Wendell Van Auken and Will Weinstein, the fund-raising effort grew out of a retreat Urology Department chair Peter Carroll, MD, put together in September 1998. It was there that the current and former UCSF patients and family members, now informally known as the Prostate Cancer Research Advocates, met each other and some of UCSF's top cancer researchers.

Advocates were tremendously helpful in allowing UCSF to get the SPORE grant, according to Marc Shuman, principal investigator for the new grant and Peter Carroll, co-principal investigator, because their financial support helped convince the NCI how committed we are to achieving our goals.

Patient care protocols

Clinical trials of new therapies for urological disorders are a departmental priority. The department and affiliated programs are conducting 38 investigational studies of treatments for genitourinary cancers, erectile dysfunction and other conditions. More than 250 patients participated in department-affiliated clinical studies last year. Several ongoing trials are listed below. For more detailed information, please contact Una Burns, 415/353-7349 or uburns@urol.ucsf.edu.

- A Pilot Study to Evaluate the Safety and Feasibility of Thermal Ablation with ThermoRods™ for Residual Prostate Cancer following External Beam Radiation Therapy
- A Phase II, Open-label Trial to Assess the Activity of ZD1839 (IRESSA™) in Patients with Recurrent Prostate Cancer who have Rising Serum PSA Levels despite Serum Testosterone <50 mg/dL
- A Randomized Phase II Trial of Sequential PC-SPES and DES, or DES followed by PC-SPES, in Patients with Androgen-Independent Prostate Cancer
- A Pilot Trial of Escalating Doses of Oral ZD1839 (IRESSA™) in Combination with Docetaxel and Estramustine in Patients with Hormone Refractory Prostate Cancer
- A Phase I/II Trial of Adoptive Immunotherapy Delivered by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma
- A Phase III Trial of Selenium and Vitamin E Cancer Prevention (SELECT)



Three-dimensional reconstruction of the neuroanatomy of the human fetal penis. Note the course of the nerves under the pubic arch. The absence of nerves in the midline position at 12:00 has allowed the strategic correction of penile curvature without causing nerve injury.

Center for the Study and Treatment of Hypospadias

The recently established Center for the Study and Treatment of Hypospadias at UCSF brings the expertise of a multidisciplinary research team to bear on this relatively common congenital defect of the penis. The center is directed by pediatric urologist Laurence Baskin, MD, a nationally recognized expert on the condition.

The center's team of pediatric urologists, endocrinologists, epidemiologists, geneticists, pathologists and basic scientists works together to determine why the defect occurs and how it can best be treated or prevented. Research has already led to new insights into the neurovascular anatomy of the genitalia. This, in turn, has suggested new surgical techniques that prevent nerve damage during corrective surgery.

In hypospadias, development of the penile urethra is incomplete. The urethral opening is abnormally placed along the shaft of the penis or on the scrotum or the perineum. Often the condition causes some degree of curvature of the penis. In patients with severe hypospadias, the genitalia may look ambiguous at birth. If the condition is not surgically corrected, patients with hypospadias may need to sit down to void and experience psychological problems with their sexuality.

Hypospadias is one of the most common congenital anomalies, according to Baskin, occurring in approximately 1 in 250 to 1 in 300 live births. Europe noted an unexplained increase in the prevalence of hypospadias in the 1970s and 1990s. In the United States, two birth defect data surveillance systems have shown an unexplained doubling in the incidence of hypospadias in the last 30 years. A Centers for Disease Control study made the intriguing observation that the incidence of severe hypospadias is increasing as well as milder forms, suggesting that the growing number of cases is not due to an increase in surveillance or reporting.

The only treatment for hypospadias is surgical repair. In experienced hands, the surgery is typically performed as an outpatient procedure when the child is between 6 to 15 months of age. Approximately 80-90 percent of children require only one operation.

"The cause of hypospadias is still unknown," said Baskin, "but one possibility could be endocrine disrupters." Basic research conducted through the center will focus on the possible roles of androgen metabolism, endocrine disrupters, molecular genetics and cellular signaling in the urinary tract. Researchers will also work to develop a good animal model for hypospadias and conduct epidemiological studies of the disorder.

For more information, visit the center's website (www.hypospadias.com).

Recognition



Peter Carroll, Donna Derr and Ken Derr



Emil Tanagho

Endowed Chair Honors Ken and Donna Derr

Chevron Corporation officers chose to honor retiring chairman and CEO Ken Derr in a unique way by establishing an endowed chair in prostate cancer at UCSF.

The phrase “company man” applies aptly to Derr. Straight out of college, he vaulted through the ranks at Chevron to hold a variety of important leadership positions. On his retirement, Chevron officers decided to honor his distinguished 40-year career with this generous gift to UCSF. The Ken and Donna Derr–Chevron Endowed Chair in Prostate Cancer is the first endowed chair at UCSF funded by a corporation.

Department of Urology chair Peter Carroll, MD, will be the first occupant of the endowed chair. “Endowments are the key to academic sustenance here at UCSF,” said Carroll. “We are pleased and honored to have the Derrs and Chevron provide such generous support for our prostate cancer work.”

The Derrs look forward to maintaining a close relationship with the holder of the chair, which will allow them to stay abreast of advances in prostate cancer research and treatment.

Emil Tanagho Honored

Former department chair Emil Tanagho, MD, was honored for his many contributions to UCSF and the field of urology at a black-tie dinner held April 21, 2001, at the St. Francis Yacht Club in San Francisco. The event, attended by 150 of Tanagho’s colleagues, family and friends, took place at the conclusion of the American Association of Genitourinary Surgeons annual meeting. Guests included the Consul General of Egypt and former UCSF chancellor Julius Krevans, MD.

Tanagho served as UCSF Urology Department chair from 1976 to 1996, building the department to its current national stature. He is widely recognized for his contributions in the areas of urinary tract embryology and development, neurourology and sexual function. His honors are numerous, including being awarded the Société Internationale d’Urologie Yamanouchi Award and the American Urological Association Ramon Guiteras Award in 2000. He is the editor of Smith’s *General Urology*, one of the most widely read textbooks of urology. He has supervised the postdoctoral research of numerous trainees, including many who hold leadership positions in the United States and abroad.

Research Laboratory Honors Frank Hinman, Jr.

The new Frank Hinman, Jr., Urological Research Laboratory honors the contributions of a UCSF clinical professor who has for many decades been a major figure in the field of urology.

Located in recently renovated quarters on the fourteenth floor of Health Sciences West on the Parnassus campus, the laboratory will provide research space for a number of Department of Urology faculty. The remodeled space includes state-of-the-art facilities for tissue culture, molecular biology and the development of models for prostatic diseases. The laboratory's work is funded by the National Institutes of Health and includes a training grant shared with the UCSF Department of Nephrology.

A clinical professor of urology at UCSF, Hinman was a founding member of the Society for Pediatric Urology in 1951 and served as president of that organization a decade later. He also served as chairman of the section on urology of the American Academy of Pediatrics, 1986-87. Hinman is the author of several texts, including *Atlas of Urologic Surgery* (1998, 2nd edition), which provides guidelines and concise illustrations for over 500 urologic procedures; *American Pediatric Urology* (1991), a definitive history of the subspecialty; and *Atlas of Pediatric Urologic Surgery* (1994), the standard operative text. His honors and awards include the Pediatric Urology Medal of the American Academy of Pediatrics (1990). A true "Renaissance man," he is not only a widely respected physician, but an accomplished sailor and artist.

The laboratory will be used by several investigators. Research projects include:

- Pediatric urologist Laurence Baskin, MD, is studying genital and urinary bladder development, with a special emphasis on cellular signaling.
- Hiep Thieu Nguyen, MD, is pursuing research in the field of obstructive uropathy in the Hinman laboratory. Drawing on his training in biochemistry, Nguyen's research focuses on how molecular processes in the kidney and bladder are altered by urinary tract obstruction.
- Tom Lue, MD, along with Ching-Shwun Lin, PhD, will be conducting research on the mechanism of female incontinence and methods of nerve regeneration after surgery or irradiation.
- Emil Tanagho, MD, has conducted extensive research on many aspects of urologic pathology. His work in the Hinman laboratory will focus on tissue engineering and neuro-stimulation.



Frank Hinman, Jr.

Frank Hinman, Jr. (left) performs experimental surgery in the early days of urological research with residents Clair Cox (middle) and Rudolf Oppenheimer.

The Frank Hinman, Jr. Urological Research Laboratory will replace the older experimental surgery laboratory pictured below, where new methods of urinary diversion were investigated.



Recent publications



Members of the department have published extensively during the past year. A few highlights are noted below.

Baskin LS.

Hypospadias and urethral development. *Journal of Urology*. 2000 Mar, 163(3):951-6.

Nudell DM; Castillo M; Turek PJ; Reijo Pera R.

Increased frequency of mutations in DNA in infertile men with meiotic arrest. *Human Reproduction*. 2000 Jun, 15(6):1289-94.

Park S; Shinohara K; Grossfeld GD; Carroll PR.

Cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. *Journal of Urology*. 2001 May, 165(5):1409-14.

Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR.

Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. *Journal of Urology*. 2001 Mar, 165(3):851-6.

Li LC; Chui RM; Sasaki M; Nakajima K; Perinchery G; Au HC; Nojima D; Carroll P; Dahiya R.

A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. *Cancer Research*. 2000 Feb 15, 60(4):873-6.

Wang Y; Sudilovsky D; Zhang B; Haughney PC; Rosen MA; Wu DS; Cunha TJ; Dahiya R; Cunha GR; Hayward SW.

A human prostatic epithelial model of hormonal carcinogenesis. *Cancer Research*. 2001 Aug 15, 61(16):6064-72.

Shekarriz B; Lu HF; Stoller ML.

Correlation of unilateral urolithiasis with sleep posture. *Journal of Urology*. 2001 Apr, 165(4): 1085-7.

Nguyen HT; Bride SH; Badawy AB; Adam RM; Lin J; Orsola A; Guthrie PD; Freeman MR; Peters CA.

Heparin-binding EGF-like growth factor is up-regulated in the obstructed kidney in a cell- and region-specific manner and acts to inhibit apoptosis. *American Journal of Pathology*, 2000 Mar, 156(3):889-98.

Santucci RA; McAninch JW.

Diagnosis and management of renal trauma: past, present and future. *Journal of American College of Surgeons*, 2000 Oct, 191(4):443-51.

Long JP; Bahn D; Lee F; Shinohara K; Chinn DO; Macaluso JN.

Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. *Urology*. 2001 Mar, 57:518-23.

Grossfeld GD; Tigrani VS; Nudell D; Roach M; Weinberg VK; Presti JC; Small EJ; Carroll PR.

Management of a positive surgical margin after radical prostatectomy: decision analysis. *Journal of Urology*. 2000 Jul, 164(1):93-100.

Wang Y; Hayward SW; Donjacour AA; Young P; Jacks T; Sage J; Dahiya R; Cardiff RD; Day ML; Cunha GR.

Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. *Cancer Research*. 2000 Nov 1, 60(21):6008-17.

Stoller ML; Bruce JE; Bruce CA; Foroud T; Kirkwood SC; Stambrook PJ.

Linkage of type II and type III cystinuria to 19q13.1: codominant inheritance of two cystinuric alleles at 19q13.1 produces an extreme stone-forming phenotype. *American Journal of Medical Genetics*, 1999 Sep 10, 86(2):134-9.

Honors & awards

Karl-Dietrich Sievert, MD, and **Richard Santucci, MD,** were each honored with a plaque and cash prize for winning essay contests at the 2000 American Urological Association, Western Section meeting in Palm Desert, California. Sievert, winner of the Miley B. Wesson Proctor and Gamble Resident Essay Contest for "Selective Sacral Root Stimulation by Using the Sinusoidal Signal and Specific Organ Frequency for the Physiological Bladder," was a visiting professor who spent his time at UCSF working with Emil Tanagho, MD. Santucci won the Joseph McCarthy Circon ACMI Physician Essay Contest, given to the best clinical paper of the meeting, for "Validation of the American Association for the Surgery of Trauma Organ Injury Scale for the Kidney." He graduated from his fellowship, which was supervised by Jack McAninch, MD, in 2000.

Eric Small, MD, associate clinical professor of medicine and urology, was appointed chair of the Genitourinary Committee of the Cancer and Leukemia Group B (CALGB), one of four national adult cancer research cooperative groups in the country. Small's committee is charged with developing a portfolio of studies in bladder cancer, renal cell carcinoma and prostate cancer.

Nicholas Holmes, MD, pediatric urology fellow, was the second annual recipient of the Frank Hinman, Jr., Award given at the April 2000 meeting of the Society for Pediatric Urology in Atlanta, Georgia. Holmes presented "Fetal Intervention for Posterior Urethral Valves: Long-Term Postnatal Outcomes," which summarized research conducted in collaboration with Laurence Baskin, MD.

Emil Tanagho, MD, professor of urology, received the Ramon Guiteras Award from the American Urological Association in June 2000. The Guiteras Award recognizes an individual's outstanding contributions to the art and science of urology.

Mustafa (Emre) Bakircioglu, MD, a 1996 graduate of the UCSF fellowship program under the direction of Tom Lue, MD, received a second-place award for the 2000 Lapedes Essay Contest. Bakircioglu was recognized for a UCSF collaboration, "The Effect of Intracavernous Injection of Adeno-Associated Virus-Brain Derived Neurotrophic Factor Gene on an Animal Model for Neurogenic Impotence." Bakircioglu now holds a position with the Urology Department at Altintepe Kizilay Medical Center in Istanbul, Turkey.

Four UCSF urology residents received awards at the Northern California Urology Residents' Seminar held on May 4, 2001. **Viraj Master, MD, PhD,** was awarded first place in the case reports category. **Shahram Gholami, MD,** was awarded second place for basic science research, **David Wu, MD,** was awarded third place for basic science research and **Donna Deng, MD,** was awarded third place for clinical research.

Donna Deng, MD, was bestowed with membership in the Alpha Omega Alpha Honor Medical Society. Deng was one of three residents from all UCSF departments selected for this honor by all 2001 UCSF medical students holding AOA membership. This honor recognizes Deng for her compassion, patient care and education of medical students.

Recent grants awarded

- Laurence S. Baskin, Principal Investigator
Urothelial Differentiation
NIH/NIDDKD Grant
- Marc A. Shuman, Principal Investigator
Peter R. Carroll, Co-Principal Investigator
UCSF Prostate Cancer SPORE
5-year NIH/NCI grant
- Peter R. Carroll, Principal Investigator
Psychosocial Counseling to Improve Outcomes in Men with Prostate Cancer
California Cancer Research Program
- Deborah P. Lubeck, Principal Investigator
Measurement of Patient Preferences for Treatment of Prostate Cancer
California Cancer Research Program
- Paul J. Turek, Principal Investigator
Genetic Comparison of the Normal, Infertile and Cancerous Human Testis by cDNA Microarray Analysis
3-year Lance Armstrong Foundation grant
- Frederic M. Waldman, Principal Investigator
Genetic Markers of Bladder Cancer Progression
5-year NIH/NCI grant

New faculty



June Chan

June Chan, ScD
Assistant Adjunct Professor,
Epidemiology & Biostatistics
and Urology

Chan earned her AB at Harvard College in applied mathematics, followed by a doctorate in science from the Harvard School of Public Health. She was a Fulbright Scholar in Sweden and completed a post-doctoral fellowship at the Department of Epidemiology & Nutrition at the Harvard School of Public Health. Chan also received a CapCURE Young Investigator Award.

As a member of the UCSF prostate SPORE, Chan will continue her epidemiological studies of modifiable risk factors for prostate cancer. These include the association between dairy and calcium intake and prostate cancer. Chan's appointment was effective January 2001.



Chris Kane

Kane, who assumed his new position in August 2001, will divide his time between the Clinical Cancer Center at Mt. Zion and the SF-VAMC, where he will develop clinical training and research programs.

Kane's research and clinical interests are focused on oncology, endourology and laparoscopy. With his arrival, the Clinical Cancer Center will be able to offer more patients minimally invasive surgery for urologic cancers.

Hiep Thieu Nguyen, MD
Assistant Professor,
Urology and Pediatrics

After earning a BS in biochemistry from UC Davis, where he was a member of the Phi Beta Kappa Honor Society, Nguyen received his MD from UCSF in 1992 and was awarded membership in the Alpha Omega Alpha Honor Medical Society. He then completed surgery and urology residencies at UCSF from 1992-1998, followed by a pediatric urology fellowship at Children's Hospital in Boston, Massachusetts. He was named to a joint faculty appointment in urology and pediatrics at UCSF in June 2000. Nguyen's current research interests lie in the field of obstructive uropathy, particularly the effects of urinary obstruction on the developing bladder and kidney. He assists Jack McAninch, MD, in overseeing the urology residency program and has helped to manage the increasing patient volume in pediatric urology at UCSF.

Christopher Kane, MD
Associate Professor, Urology, Chief
of Urology, SFVAMC

After earning a BS in mechanical engineering from UC Davis and an MD from the Uniformed Services University of the Health Sciences, Bethesda, Maryland, Kane completed a surgical residency at the UC Davis East Bay General Surgery Program in Oakland, California, and a urology residency at the Oakland Naval Medical Center and UCSF. He comes to UCSF from the Naval Medical Center San Diego, where he directed the residency program. He also headed Endourology, Stone Disease and Laparoscopy at that institution, served as site principal investigator for the Center for Prostate Disease Research and was vice-president of the Uniformed Services Urology Research Group.



Hiep Nguyen

Top residents match to UCSF



Adam Hittelman

Adam Hittelman, MD, PhD

Hittelman earned his MD from New York University School of Medicine and his PhD in microbiology from New York University, where he studied the glucocorticoid receptor with Michael J. Garabedian, PhD. He was awarded a BA with honors in molecular and cell biology from the University of California, Berkeley. He served as a Joseph Alexander Foundation Fellow from 1999-2001.

Sarah Janssen, MD, PhD

Janssen earned her MD and PhD from the University of Illinois College of Medicine, Urbana-Champaign. She was also awarded an MS from that institution and a BS from Illinois State University. Her most recent research studied the role of estrogen in the male reproductive tract and the formation of calculi in the epididymis. Her hon-

ors and awards include membership in the Alpha Omega Alpha Honor Medical Society, the Patricia J. and Charles C.C. O'Morchoe Leadership Award of the Medical Scholars Program, and the Swartz-Flood Award for best student oral presentation, Medical Scholars Program Retreat.

Susan Logan, MD

Logan earned her MD from the University of California, San Francisco School of Medicine and a BA in molecular and cell biology from the University of California Berkeley, where she graduated Phi Beta Kappa. While at UCSF, she conducted a retrospective analysis of approximately 500 men who underwent transrectal ultrasound and identified risk factors for cancer extension.



Sarah Janssen



Susan Logan

Paul Stempen
Medical Illustrator
and Painter
(1957-2000)



In memoriam

The Department of Urology lost an extraordinarily talented medical illustrator, and the art world a successful and prolific painter, when Paul Stempen died December 31, 2000 of a sudden heart attack.

Stempen grew up in Philadelphia and after earning his BA in art at Rutgers, came west to earn an MA from the former UCSF Graduate Program in Medical and Biological Illustration. UCSF clinical professor of urology Frank Hinman soon enlisted the talented freelancer to prepare the illustrations for Hinman's *Atlas of Urologic Surgery*. In four years, Stempen made 1,700 illustrations for this reference work.

Stempen became senior medical illustrator in the department, working at UCSF for more than 12 years. He collaborated with Hinman and other faculty members, providing illustrations for their journal articles, books and urology meeting posters. He created the department's website and designed and illustrated its newsletter.

The beauty and detail of his drawings won Stempen many awards over the years. In 2000 he was given the William P. Didusch Award of the American Urological Association in recognition of outstanding contributions to urologic art.

Stempen's paintings were successfully shown in many gallery shows. Often they featured much-used vehicles parked on San Francisco's steep streets. Stempen died just days before a solo show of his works opened at the Campbell-Thiebaud San Francisco Gallery.

"Paul had an in-depth knowledge of anatomy, which exceeded that which most of us had. His ability to transform our concepts into medical illustrations was wondrous," said Peter Carroll, MD, department chair. "His talents, warmth and grace will be greatly missed."



Faculty

Peter Carroll, MD
Professor and Chair
Specialty: Urologic Oncology

Tom Lue, MD
Professor and Vice Chair
Specialty: Erectile Dysfunction
and Neurourology

Jack McAninch, MD
Professor and Vice Chair
Specialty: Urologic Trauma and
Urogenital Reconstructive Surgery

Laurence Baskin, MD
Associate Professor
Specialty: Pediatric Urology

June Chan, ScD
Assistant Professor
Epidemiology & Biostatistics
and Urology

Gerald Cunha, PhD
Professor, Anatomy, Obstetrics and
Gynecology, and Urology

Rajvir Dahiya, PhD
Professor

Gary Grossfeld, MD
Assistant Professor
Specialty: Urologic Oncology
and BPH

Frank Hinman, Jr., MD
Clinical Professor

Christopher Kane, MD
Associate Professor
Specialty: Laparoscopy and
Oncology

Ching-Shwun Lin, PhD
Associate Professor

Deborah Lubeck, PhD
Director, Urology Outcomes
Research Group

Hiep Thieu Nguyen, MD
Assistant Professor
Specialty: Pediatric Urology

Renee Reijo Pera, PhD
Assistant Professor, Genetics,
Obstetrics and Gynecology,
Physiology, and Urology

Mack Roach III, MD
Professor, Radiation Oncology
and Urology
Specialty: Radiation Oncology

Katsuto Shinohara, MD
Associate Professor
Specialty: Urologic Oncology
and Urologic Ultrasonography

Marc Shuman, MD
Professor, Medicine and Urology
Specialty: Medical Oncology

Eric Small, MD
Professor, Medicine and Urology
Specialty: Urologic Oncology

Marshall Stoller, MD
Professor
Specialty: Endourology,
Laparoscopy and Stone Disease

Emil Tanagho, MD
Professor
Specialty: Neurourology,
Reconstructive Urology, Urinary
Incontinence and Urodynamics

Paul Turek, MD
Associate Professor
Specialty: Male Infertility and
Reproduction

Frederic Waldman, MD, PhD
Professor, Laboratory Medicine
and Urology

Editor
Peter R. Carroll

Managing Editor
Malinda Walker

Contributing Editor
Leslie Lingaas

Design
Victoria Maier

UCSF Urology is published by
the department of urology to
present developments in re-
search and clinical practices
made within the department.

Please send comments and
inquiries to:

Newsletter staff

UCSF Department of Urology
San Francisco, CA 94143-1695

415/885-7723

mwalker@urol.ucsf.edu

University of California
San Francisco

UCSF

Department of Urology